October 10, 2014 -- ContraFect Corporation, a New York biotech, and China's National Institute for Viral Disease Control and Prevention, China CDC (IVDC) formed a collaboration to advance ContraFect's universal treatment for flu. CF-404, currently in pre-clinical development, is comprised of three fully human monoclonal antibodies. In animal models, using a low dose, it provided protection against all human strains of flu, including pandemic strains. The IVDC will conduct tests of CF-404 on China flu strains. Financial details were not disclosed. More details....
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
